Aspeya, owned by Philip Morris International, operates independently and utilizes Fertin Pharma's oral technology platform. Fertin Pharma, a wholly owned subsidiary of Aspeya, is a CDMO that develops and manufactures innovative oral and intra-oral delivery systems.
Products, services, technology
We’re applying our expertise to innovate in the field of wellness and healthcare in four areas of focus:
- Cannabinoids
- Inhaled therapeutics
- Nicotine replacement therapy (NRT)
- Consumer health
Cooperation possibilities
Innovative pharmaceutical and consumer life sciences products, Innovative life sciences products & technologies, CDMO business for inhaled, oral, intra-oral products and delivery systems, Licensing and partnerships: innovative products and technology platforms.
- https://www.aspeya.com/
- +41 78 266 62 58
- Send an email
- Begoña Carreño
Some insights
We are driven by the exciting and unique goal of revitalizing, repurposing, and reimagining existing therapies to address unmet consumer and patient needs.